{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:00:06Z","timestamp":1790614806126,"version":"4.1.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>While dupilumab is highly effective in managing moderate-to-severe atopic dermatitis (AD) through targeted IL-4\/IL-13 receptor antagonism, its broader immunomodulatory effects warrant careful clinical scrutiny. We report the case of a 63-year-old male who developed ulcerative colitis (UC) following dupilumab therapy. Although his cutaneous condition improved rapidly, the patient developed acute gastrointestinal distress, including hematochezia and tenesmus, within three months of initiating therapy. Subsequent colonoscopy and histopathological analyses confirmed the diagnosis of UC. Discontinuation of dupilumab was followed by a robust clinical and endoscopic remission. Longitudinal immunohistochemical profiling of the colonic mucosa demonstrated elevated IL-17 and suppressed IL-4 expression during active colitis, which normalized upon clinical recovery. These findings offer hypothesis-generating evidence indicative of a localized Th2-to-Th17 immune shift. Although inherently limited as a single-patient report, this case underscores the critical necessity for multidisciplinary vigilance regarding paradoxical Th17-driven inflammation in patients undergoing IL-4R\u03b1 blockade.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1875748","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:42:45Z","timestamp":1783485765000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Dupilumab-associated ulcerative colitis: elucidating the pathomechanistic link between Th2 blockade and Th17 polarized intestinal inflammation"],"prefix":"10.3389","volume":"17","author":[{"given":"Fanghui","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Binzhou Medical University Hospital","place":["Binzhou, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital for Skin Diseases, Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Binzhou Medical University Hospital","place":["Binzhou, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aili","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Binzhou Medical University Hospital","place":["Binzhou, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Binzhou Medical University Hospital","place":["Binzhou, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1361005","article-title":"Unraveling the skin; a comprehensive review of atopic dermatitis, current understanding, and approaches","volume":"15","author":"Afshari","year":"2024","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: a review of its use in the treatment of atopic dermatitis","volume":"78","author":"Gooderham","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00984-8","article-title":"Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies","volume":"19","author":"Cozzi","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2024.02.011","article-title":"Paradoxical psoriasis","volume":"42","author":"Abdelghaffar","year":"2024","journal-title":"Dermatol Clin"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.03.013","article-title":"T helper 2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17\u2013type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases","volume":"142","author":"Bridgewood","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.tips.2024.08.003","article-title":"Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments","volume":"45","author":"Wangchuk","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12876-021-01803-8","article-title":"Anti-IL-4Ralpha monoclonal antibody dupilumab mimics ulcerative colitis: a case report","volume":"21","author":"Shimodaira","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16928","article-title":"Ulcerative colitis during dupilumab therapy in a patient with atopic dermatitis","volume":"50","author":"Seishima","year":"2023","journal-title":"J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1578","article-title":"Psoriasis risk in patients with atopic dermatitis treated with dupilumab","volume":"161","author":"Lin","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7247238","article-title":"A comprehensive review and update on the pathogenesis of inflammatory bowel disease","volume":"2019","author":"Guan","year":"2019","journal-title":"J Immunol Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101520","article-title":"Unexpected connections of the IL-23\/IL-17 and IL-4\/IL-13 cytokine axes in inflammatory arthritis and enthesitis","volume":"58","author":"Bridgewood","year":"2021","journal-title":"Semin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa568","article-title":"Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy","volume":"60","author":"Bridgewood","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14958","article-title":"Development of IL-17A inhibitor-induced atopic dermatitis-like rash in psoriasis patients: insights into immune shift","volume":"33","author":"Li","year":"2024","journal-title":"Exp Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1875748\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:43:10Z","timestamp":1783485790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1875748\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":14,"alternative-id":["10.3389\/fimmu.2026.1875748"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1875748","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"article-number":"1875748"}}